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Over 30 years have passed since the genetic material of most organisms was shown to be deoxyribonucleic acid (DNA). While a considerable amount of information on the fine structure and function of bacterial DNA has emerged during this time, the enormously greater complexity of eukaryotic DNA has, until recently, hindered progress in its elucidation.' During the past 10 years important methodological and conceptual advances have occurred that are rapidly changing this and at the same time opening up the study of DNA in man and its role in human pathology. Indeed, this has become one of the most exciting and rapidly growing areas of science.
Technological advances
The advances in recombinant DNA technology,23 which are now so widely used, entail the ability to recombine small sequences of human or other DNA (up to 50 kilobase pairs) into microbiological cloning vectors such as plasmids, bacteriophage, or cosmids; cleave double stranded DNA at specific sites with bacterial restriction -endonucleases, separate the resultant small fragments electrophoretically, denature them to single stranded form and transfer to a solid matrix such as nitrocellulose; and identify these immobilised DNA (or RNA) fragments in picogram amounts by allowing them to reanneal with a specific complementary DNA sequence (probe) labelled either with 32phosphorus or biotin containing nucleotide derivatives. The probe sequence is usually prepared from a recombinant vector, but it can also be chemically synthesised in the form of small Accepted for publication 16 July 1986 base pairs) oligonucleotides specifying the required complementary sequence.
CLONING HUMAN DNA SEQUENCES
The major impact of cloning recombinant DNA sequences has been in the ability to follow through advances in the preparative biochemical or immunochemical purification of proteins, nucleic acids, and even whole chromosomes. Relatively abundant proteins of functional interest have been purified and their amino acid sequences identified either in whole or in part. This sequence can be used as the basis for the chemical synthesis of a mixture of possible nucleotide bases coding for a subset of five to 10 amino acids. These are then used as probes to identify recombinant clones containing the true homologous sequence in "libraries" of non-specifically cloned expressed (mRNA) sequences (cDNA library) or of total DNA (genomic library).4"Genes for less abundant proteins can be isolated by enrichment for the specific mRNA by immunoprecipitation of the polysome bound message, or, more effectively, by screening cDNA libraries cloned into "expression" vectors with specific antibody, permitting direct identification of suitable recombinant clones.6 7 Strategies entailing the isolation of a series of overlapping clones have made it possible to map and ultimately sequence large genes such as human factor VIII, which span almost 200 kb of DNA.8 DNA obtained from specific human chromosomes separated by flow cytometry or isolated from rodenthuman somatic cell hybrid cells can also be digested, inserted into a cloning vector, and amplified to form a chromosomal library.9 This can be used to isolate short unique sequences, more or less at random, from the chromosomal library. Short unique segments are 1282 unlikely to be coding for functional products but are potentially useful as markers for gene mapping.10 There is also increasing interest in the development of strategies that permit larger amounts of DNA to be cloned, which could help in the isolation of disease genes whose function is entirely unknown but whose location has first been identified by mapping with random probes. Potential strategies include the transfection of human DNA into non-human cells in culture and selection by means of cotransfected genes coding for a biochemically selectable product."
Clones showing stable integration of large human DNA fragments (in the region of 100-10 000 kb) may be isolated in this way.12 Other understanding of the kinetics and stability of DNA Wright duplex formation comes from studies of DNA hybridisation in solution rather than from studies of matrix immobilised fragments, although the conclusions are thought to be qualitatively similar. ' 19 20 Variations in hybridisation conditions are so important in DNA analysis that a brief consideration of the major variables is necessary.
Reannealing of complementary fragments occurs initially by the association of a few pairs of complementary nucleotide bases by hydrogen bonding (nucleation), allowing the remainder of the sequence to reanneal if it is in the correct register.2 ' The rate of duplex formation is influenced by the length and concentration of complementary DNA fragments, the pH and temperature of the reaction, the concentration of formamide or other denaturing agents (if present) and the salt concentration.20 22 The rate of formation and stability of the resultant duplex is critically dependent on the hybridisation conditions, degree, and location of base mismatching.23 The conditions favouring duplex formation and stability include high salt (1 M (Na+)), which may serve to neutralise the repulsion of phosphate residues on opposite strands, and a temperature that is about 20-25°C below that at which the duplex melts (Tm; Tm is the temperature at which a given DNA duplex is 50% associated at equilibrium. A Tm value of about 85°C is expected for total human DNA probed with a precisely matched sequence 1 kb in length.) The higher the temperature, the greater the requirement for precise base matching. Hybridised filters are commonly washed either at increased stringency (Tm-15°C, 0-015-0-15M (Na+)) or reduced stringency (Tm-30°C, 0-9M (Na+)), depending on the intention to identify or eliminate signals from poorly matched hybrids. The limits of resolution obtained in this way are such that on the one hand synthetic oligomers, only 17 base pairs in length, can form a stable duplex with human genomic DNA and yet fail to do so if there is a single base mismatch within that sequence. 24 25 This method of directly recognising a base change within a functionally important sequence is likely to be increasingly important in the diagnosis of inherited disease and in the detection of mutant oncogenes in neoplastic tissues. At the other extreme of resolution, families of related sequences that have diverged by as much as 30% can be detected using appropriately permissive hybridisation conditions.22
In contrast to DNA from prokaryotic organisms, human DNA is highly heterogeneous, as shown by the fact that it reassociates at rates that vary by about seven orders of magnitude.20 This is because sequences that are repeated throughout the genome are at higher concentration and therefore will reassociate much more rapidly than unique or single copy sequences for a given amount of total DNA. On this (10-4-10-8) , while estimates of spontaneous somatic mutation, as measured in vitro, are some orders of magnitude higher, even when the number of replicated cycles is taken into account.32 Copy errors occurring during 1283 DNA replication account for most mutations, leading mainly to base pair substitutions, although changed codon reading frames arising from insertion or deletion of bases (frameshifts) and larger structural rearrangements also occur. While it is hazardous to extrapolate from in vitro data, it is likely that mutation is occurring at an appreciable rate in somatic cells, more so in rapidly dividing cells, so that mutations that increase growth may contribute to neoplasia in dividing tissues, while in non-dividing tissues mutations causing loss of function and cell death may lead to degenerative changes. DNA repair and immunological or other means of removing mutant somatic cells are likely to have a vital role in maintaining the balance of health and disease. 30 The functional consequences of mutation, whether within germinal or somatic cells, depend both on the gene product and on the nature and location of the change within the gene, which is now thought of as including both coding (expressed) and non-coding sequences. The extent of this mutational diversity will now be discussed in the context of the genomic architecture, with particular reference to human disease. Starting from the 5' end of the gene shown schematically in fig 1, are certain sequences that tend to be conserved in evolution and which are necessary for efficient transcription of the messenger RNA (mRNA). In eukaryotes there are four or five known sequences contributing to promoter function, some or all of which are present in all functional genes. These are thought to be necessary for binding of RNA polymerase II, which synthesises mRNA in a 5'-3' direction. These sequences include the TATA box, CCAAT box, a GC rich region, and finally the transcription initiation (cap) site, which lies close to a sequence presumed to be necessary for binding of Adult polycystic kidney (types I, II, IV) (7) disease (16) ax,-antitrypsin deficiency (14) Cystic fibrosis (7) Isolated growth hormone deficiency (type IA) (17) Retinoblastoma (13) Antithrombin III deficiency (1) Wilms' tumour (I 1) Familial hypercholesterolaemia (type Ila) (19) Aniridia (I I) Familial apolipoprotein CII Adrenoleukodystrophy deficiency (19) (X) Factor X deficiency (13) Peroneal muscular atrophy (X) Chorionic somatomammotropin deficiency (17) Choroideremia (X) Congential adrenal hyperplasia (21-hydroxylase deficiency) (6) Retinitis pigmentosa (X) Adenosine deaminase deficiency (20) Fragile X syndrome (X)
Diabetes mellitus (MODY) ( 11) Duchenne muscular dystrophy (X) Immunoglobulin K-chain deficiency Becker muscular (2) dystrophy (X) Amyloidotic polyneuropathy (18) Norrie's disease (X)
Carbamoyl phosphate synthetase 1 deficiency (2) Ocular albinism (X) Haemophilia A (factor VIII deficiency) (X) Haemophilia A (X) Haemophilia B (factor IX deficiency)
Glycerol kinase deficiency (X) Ornithine transcarbamylase deficiency (X) In the case of the diseases diagnosed using specific gene probes, genetic heterogeneity may limit their application to selected families. Genetic diseases that can be diagnosed using non-specific probes located within about 10 centiMorgans are listed. In many cases these methods are restricted to research rather than routine clinical application.
mRNA to the ribosomes. Mutations affecting regulatory sequences have been identified in patients with a positive or P positive thalassaemia, which are associated with reduced transcriptional activity (table 1). After the transcription initiation site there is a 5' untranslated region of variable length that ends in a conserved and presumably functionally important sequence immediately preceding the first codon (ATG), which codes for methionine. The importance of such transcribed but untranslated regions has been emphasised by the finding that such a region regulates the stability of mRNA transcripts coding for the c-myc oncogene.33 Its deletion in some patients with Burkitt's lymphoma may therefore change the expression of this oncogene and contribute to the genesis of this tumour.
Further upstream (towards the 5' end) from promoter sequences or sometimes in intervening sequences or remote 3' sites there may be enhancer sequences important for increased or tissue specific 1285 expression of genes. A role for enhancers in the genesis of certain tumours has been suggested by the translocation of c-myc oncogenes (on chromosome 8) to the vicinity of strong immunoglobulin enhancers (on chromosomes 14, 2, or 22) in some patients with Burkitt's lymphoma, although in most cases the break point lies proximal to the enhancer.33 It has been suggested that a variable tandem repeat (VTR) sequence located 3' to the c-Ha-ras oncogene may also be an enhancer, perhaps explaining the presence of unusual VTR alleles in patients with various solid and leukaemic tumours. 34 Coding sequences are separated by intervening sequences of varying length, which are transcribed but not translated and are removed by being "spliced out" in the nucleus. Splicing of messenger RNA seems to depend on the precise recognition of specific sequences of nine to 12 bases at the 5' and 3' exonintron junctions, which can be changed in diseases such as thalassaemia (table 1) . Splicing is, in many cases, necessary for stabilisation of the mRNA and for export to the cytoplasm. Other sequences within the intron have also been shown to be necessary for recognition by the splicing enzymes. In procollagen genes there are about 50 introns, each of which requires correct splicing3" so that mutations affecting this process are likely to be identified with the availability of cloned collagen sequences in heritable disorders affecting these molecules (table 1) .
Most mutations affecting gene expression are base pair substitutions within the coding sequences (table 1). Our current knowledge of specific mutations in most diseases is heavily biased towards the more readily identified changes such as deletions and gross rearrangements. Moving towards the 3' end of the gene, the last exon is terminated by a stop codon (UAA, UAG, or UGA), which terminates translation, although transcription is continued for a variable distance towards the 3' end of the gene where it stops several hundred base pairs 3' to the polyadenylation signal sequence (AATAAA), which is the site of mRNA cleavage. Mutations resulting in loss of the polyA signal have been found in a-chain positive and P-chain positive thalassaemia, resulting in an abnormally long globin message (table 1). In addition to nuclear splicing, most eukaryotic mRNAs are modified before export through the nuclear envelope by capping the 5' end by addition and methylation of a Gppp residue to a pyrimidine and also by tailing the 3' end by addition of 50-150 adenylic acid residues. Differential processing of mRNA in the cytoplasm is another means of regulating gene expression and is therefore a potential site of mutational change (fig 1) .
One final way in which DNA organisation is relevant to human disease is in the rearrangement or irreversible loss of large segments of DNA during the course of cellular differentiation.3" This phenomenon occurs, but may not be unique to, the immunoglobulin (Ig) and T cell receptor loci and serves to generate diversity and activate genes at appropriate developmental stages. This type of mechanism is already important for diagnostic pathology. The arrangement of the Ig heavy chain cluster in germ line-that is, undifferentiated DNA-is different from that in a cell that has progressed along the path of B cell differentiation as a result of local rearrangements of V, D, and J segment genes. Thus a histologically undifferentiated lymphoma cell can be classified as B or non-B lymphocyte in origin.37 A second class of rearrangement occurs in B cell differentiation entailing the orderly switching of expressed heavy chain genes (class switch)38 and seems to be initiated by deletion of several genes located 5' to the expressed heavy chain by a recombinational process. Both of these types of rearrangement may be important in the pathogenesis of certain types of lymphoid tumour, as they appear to be relatively prone to the occurrence of rearrangements, some of which can change the expression of cellular oncogenes. it is simpler to make a direct diagnosis-that is, by demonstrating a specific abnormality in the patient-at the level of the gene product (mRNA, protein) . Only recently has a general strategy been suggested that might make it possible to make a direct diagnosis at the DNA level in a variety of genetic disorders,40 but this is far from being in routine use in diagnostic laboratories. Direct diagnosis at the level of the gene product is not, however, usually a feasible proposition in the case of prenatal diagnosis, where the ability to show abnormality in the DNA would circumvent several problems such as age and tissue specific expression. Despite this it is often only possible to make an indirect diagnosis at the DNA level using a cloned gene specific to the disease. Indirect Wright diagnosis here implies diagnosis by association within the context of a family study. The need to resort to indirect diagnosis is an irritating necessity in the context of diagnosis using specific cloned genes but, in the context of Mendelian disorders whose molecular nature is unknown, it is an extremely powerful approach that looks set to make a greater impact both on our understanding and on the diagnosis of genetic disease. The rationale for applying such an indirect diagnosis is best discussed in the context of the restriction fragment length polymorphism (RFLP) RESTRICTION 
FRAGMENT LENGTH POLYMORPHISM
The idea of using RFLPs to map indirectly Mendelian disorders whose molecular basis is unknown was first suggested by Solomon and Bodmer41 and later discussed at length by Botstein et al. 42 It exploits the presence of an unexpectedly high prevalence of DNA sequence variation throughout the genome, much of which is potentially detectable when it leads to the loss or gain of a restriction endonuclease cleavage site, with resultant variation in restriction fragment length. Fig 2 shows the detection of RFLPs. It has been estimated that on average 1 in 300 base pairs shows common or polymorphic variation in the general population.43 By screening DNA transfers from a panel of normal subjects cut with various restriction enzymes, one or two enzymes are usually found that identify normal and variant fragments due to loss or gain of a cleavage site. These variants are commonly located some 2-20 kb outside the sequence that shows homology with the probe and are generally found in non-coding DNA sequences. As they do not produce a change in phenotype they are presumably unaffected by natural selection and therefore have accumulated by random mutation over enormous lengths of evolutionary time.
The requirements for indirectly identifying the location or presence of a gene using RFLPs in a family study can be summarised as follows: 1 A clinically and genetically-homogeneous group of families should be available, in which members are unambiguously assigned to affected and unaffected groups. A limited amount of genetic heterogeneity between families can be tolerated in the analysis, but too much will obscure the result. 2 The probe or RFLP site must be situated within a genetic distance that allows one to distinguish linked from unlinked genes. In practice a genetic distance less than 30 centiMorgans (one centiMorgan ( In 1980 Botstein et a!42 suggested that it would be possible to identify indirectly the location of any disease gene by linkage analysis using RFLPs, without having any knowledge of the specific gene responsible, or of its products. It was suggested that a limited number (150-200) of RFLP markers spaced at about 20cM intervals would be sufficient to do this as the total haploid genetic length is about 3300cM. The average size of a human chromosome is about 150cM so that five to 10 suitably spaced markers per chromosome should be sufficient. Table 2 gives examples of Mendelian disorders whose molecular basis may or may not be known, but which have been mapped indirectly using recombinant DNA probes and RFLPs. The number of families required to establish linkage using random probes varies with the genetic distances entailed. the mode of inheritance, and the structure of the families.48 Almost invariably the required number of families is larger than that predicted from theoretical considerations because of uncertainty about the linkage phase, more so in autosomal recessive disease. Highly polymorphic multiple allele markers are considerably better than the conventional two allele RFLP systems, as correspondingly more families are informative for linkage.49 Large families are preferable for establishing a new linked marker as they tend to give more information on the linkage phase and because genetic heterogeneity becomes less of a problem. In practice mapping using RFLPs is usually complemented by the identification of patients with chromosomal rearrangements or deletions that further localise the gene.5054 The identification of a gene before rather than after the identification of its product ("reverse genetics") has been achieved with several oncogenes and may soon become a reality with genes for inherited disease. In Duchenne muscular dystrophy (DMD) the gene has been localised to within 2 cM by RFLP mapping,55 but to within about 600kb by the identification of small deletions and an X to autosomal translocation breakpoint situated close to the DMD locus.53 54 The application of such RFLP mapping techniques to routine clinical diagnosis is likely to be a process of slow evolution rather than immediate transition. The initial goal is to obtain RFLPs within 1OcM on each side of the gene (bridging markers), thus reducing the predictive error to about 1%. This amount of error is probably acceptable in the diagnosis of serious genWright etic disorders and is likely to lead to wide application, provided that genetic heterogeneity has been shown to be minimal. The ability to isolate DNA from the fetal chorionic trophoblast during the first trimester of pregnancy potentially provides a real advance over second trimester diagnosis when coupled with such DNA probing techniques, although the safety of chorion biopsies has yet to be fully shown.56 DIRECT 
DIAGNOSIS OF GENETIC DISEASE
There are several problems associated with the use of specific gene probes in the diagnosis of genetic disorder. These problems arise in two different contexts: first, where gene structure or expression is changed in a disease and there is little doubt that the cloned gene is the site of primary abnormality; secondly, where the available understanding of the disease suggests that a particular cloned gene is a good candidate for the site of primary abnormality-but this has been hard to confirm at the level of gene expression for any of a variety of reasons. In this case the problem is to screen a "candidate" gene for its likely role in the disease process, without initially resorting to a comparison of normal and presumed abnormal DNA sequences. In the former case the cloning and sequencing of the genes are usually necessary at some stage. More recently, an understanding of the molecular nature of particular mutations has made it possible to synthesise small oligonucleotide probes, specific either to the normal or abnormal gene sequence, which can distinguish between these two alternatives under appropriate hybridisation conditions. This method has been applied to the direct diagnosis of the Piz allele responsible for a1-antitrypsin deficiency25 and to certain haemoglobinopathies.26 60 61 A third approach to the direct diagnosis of molecular disease has not yet been fully exploited but arises from the ability to detect small mismatches in RNA-DNA hybrids using high specific activity RNA probes specific for the normal DNA sequence and ribonuclease A which will recognise and cleave mismatched hybrids.40 Mismatched hybrids will occur when there is a base substitution in the DNA of the affected patient and can lead to the identification of abnormal RNAse cleavage products following electrophoresis. If this technique is found to be generally applicable it would provide an important advance in the use of DNA in the diagnosis both of genetic disorders and of somatic mutation in oncogenesis. In general, a group of unrelated patients with a particular genetic disorder are likely to have mutations affecting any of several different sites within the gene, each of which produces abnormal function. This will be the 1289 general expectation unless there is either a very low mutation rate within that gene or there has been strong selection in favour of a particular mutation in the past, so that it is found in a sizeable proportion of disease bearing patients. Huntington's chorea may be an example of the case where the mutation rate is low, with the result that most of the cases in north America are probably descended from a few original mutations introduced in the seventeenth century. 63 Sickle cell anaemia and some of the thalassaemia mutations may be examples of the second mechanism, in which natural selection has amplified a few ancient mutations in certain populations.61 Most genetic disorders may not come into either category, so that it will not be feasible either to identify specific restriction fragment variations or develop the appropriate oligomers for each mutational type. A general method for detecting mismatches within a relatively large cloned sequence40 will perhaps help to fill this diagnostic gap, although it is still likely to be applied in the context of a family study wherever possible.
DNA probes in oncogenesis
Although the use of DNA probes in the diagnosis of microbiological disease is already of considerable importance,64 besides the area of genetic pathology, the biggest impact of recombinant DNA technology in medicine is likely to be in the study of oncogenesis. Several excellent reviews of this area have been published,31 65-68 but it is worth emphasising some specific areas in which DNA analysis is increasingly relevant to diagnosis.
It is now beyond reasonable doubt that a variety of specific somatic mutational changes accompany the progression of individual tumours, although it is hard to analyse the clinical importance of any one of these outside the context of a complex and evolving cellular phenotype. The analysis of tumour pathology has gradually progressed from the cellular to the chromosomal and now to the DNA level, where the identification of somatic genetic changes are beginning to elucidate phenotypic correlates of malignancy at other levels of analysis. The implications for typing the nature and progression of individual tumours are clear. There are three areas for which DNA analysis is particularly relevant to the study of oncogenesisnamely, inherited predisposition to cancer; DNA changes associated with the initiation of tumour growth; and DNA changes associated with tumour progression.
INHERITED PREDISPOSITION
Inherited preredisposition to cancer is well established in a small number of Mendelian disorders, some of which have been mapped to chromosomal 1290 regions as a result of visible chromosomal abnormalities. For example, a small proportion of patients with retinoblastoma and Wilms' tumour (nephroblastoma) have deletions in chromosomes 13 and 1 1, respectively.6970 In some of these disorders there seems to be an interaction between the inherited mutation that predisposes to a particular type of cancer and secondary somatic mutational events. The analysis of retinoblastoma (Rb) tumours suggests that a secondary mutation is required for tumour development.69 This results in loss of the normal allele(s) leading to hemizygosity or homozygosity of the Rb allele. The secondary mutation seems to occur either by mitotic recombination, non-dysjunction, or gene conversion. by incorporation into exogenous retroviruses as viral or v-onc genes and subsequent reinsertion into the host genome; secondly, by changed regulation following the insertion of retrovirus into adjacent sequences; thirdly, by somatic mutation within the c-onc itself. These proto-oncogenes are thought to have a normal role in such diverse activities as the control of differentiation, cell division, growth factor production and response.68 Mutational disturbance of c-onc function is thought to be associated with the initiation or progression of the sequence of genetic and epigenetic changes associated with neoplasia.
Retroviral oncogenes generally show mutational differences from their proto-oncogene equivalents at several sites, only some of which may be crucial to neoplastic transformation. The retrovirus has a single stranded RNA genome, which can infect the host and become copied into DNA by the action of reverse transcriptase. It may then either remain as an integrated provirus or be transcribed into RNA allowing expression of its own gene products, which permit the repackaging and release of infective virus. Mutational damage can occur as a consequence of insertion into the host genome.65 A surprisingly high proportion (0 5%) of the DNA of some mammalian species contains proviral sequences,72 which seem to be contained by cellular mechanisms that prevent expression or transmission between cells.
Most proto-oncogenes have been discovered through their homology with retroviral v-onc derivatives, so that our current knowledge of protooncogenes is biased by this perspective. A dozen or so c-onc genes that have no retroviral equivalents have now been identified from tumour cells by their ability to transform cells in culture. While it is clear that only a minority of retroviruses carry oncogenes, those that do can subvert the function of their cellular c-onc equivalents and give rise to neoplasia. Retroviruses that do not contain v-oncs are also potentially oncogenic, although less dramatically so. They seem to act by random insertion into the host genome, occasionally disrupting the regulation of cellular protooncogenes and initiating tumour development.65 The best example in man is the group of human T cell leukaemia viruses (HTLV I-III).74 HTLVI expression is strongly associated with adult T cell leukaemias and lymphomas that show a tendency both to geographical and to familial clustering. Some insight into the mechanism of action of HTLVI is beginning to emerge with the identification of a sequence that is capable of activating the expression DNA analysis in human disease of remote but as yet unidentified host genes, possibly including certain growth factor receptors, which are expressed at a high level in these tumours. 73 Although the role of retroviruses in oncogenesis has attracted most attention to date, their association with neurological, cardiovascular, and other disorders has been observed in animals and man,74 which will undoubtedly be elucidated by the use of cloned sequences to probe diseased tissues for expression or integration of viral sequences.
DNA CHANGES ASSOCIATED WITH TUMOUR PROGRESSION
It seems likely that only a few human cancers are pre-1291 cipitated by retroviral insertion, but this work has highlighted the changes occurring in their normal cellular counterparts during tumour progression. Two major types of change have been found to occur in proto-oncogenes in neoplastic tissue-namely, increased expression of a normal sequence and normal expression of a mutant sequence.
Increased expression of certain gene products has been known to occur in viral oncogenesis for a long time, but amplification or overexpression of some cellular oncogenes has now been shown in a wide variety of human tumours and tumour cell lines (table 3) . The most striking example in man is the amplification of apparently normal N-myc genes in stage III and IV Table 3 Human tumours associated with mutations in oncogene sequences* Evidence that neither mutation nor changed expression of a single proto-oncogene is normally sufficient to initiate neoplasia de novo was obtained by Weinberg et al. 79 They cultured untransformed cells directly from animals, rather than studying the transformation of cells that had already been in culture for long periods, and showed that more than one oncogene was required-for example, ras and mycto transform cells. The multistep nature of carcinogenesis has been known for a long time, but only now is its molecular basis beginning to emerge.66 68 Most proto-oncogenes identified so far have functions Wright closely related to growth control, suggesting that there may be only a limited number of such genes (less than 50) with major effects on oncogenesis. There will almost certainly be many more with minor effects on neoplastic progression. This might lead to a useful distinction between major and minor oncogenes on some empirical basis, such as their ability to transform NIH-3T3 cells.
A progression of genetic and epigenetic changes, combined with hormonal or other environmental factors, are likely to be necessary for the gradual transition from the preneoplastic state to the undifferentiated invasive neoplasm with metastatic potential. At clinical presentation about 15% of all human tumours contain transformationally active ras oncogenes.3' Other transforming genes that lack v-onc counterparts have also been found in such tumours. Chromosomal rearrangements such as amplification and translocation often occur, some of which seem to confer a growth advantage (table 3) . The sometimes rapid progression of tumours in vivo, coupled with the in vitro finding of an increased rate of mutational change with increased metastatic potential, suggests the further possibility that the packaging or repair of DNA in chromatin may be changed so as to make it more sensitive to mutation in tumour cells. 80 Already certain tumours can be typed and staged by means of DNA analysis. Lymphomas can be classified as T or B cell in origin according to whether they show germ line or differentiated arrangements of immunoglobulin genes.37 Neuroblastomas can be classified using DNA-RNA hybridisation according to the level of N-myc expression, which correlates with increasing malignancy,75 as does ras expression in other types of tumours.3' As our knowledge of the functions of proto-oncogenes increases new opportunities for treatment may emerge so that the analysis of major and minor oncogene structure and expression in tumours and preneoplastic tissue looks set to become an integral part of diagnosis and treatment.
Future prospects
It is salutory to try and envisage the extent to which DNA analysis will become an established part of clinical investigation in the future. Future applications in the diagnosis of Mendelian disease and the typing and staging of neoplasms have been discussed at length.
Less obvious areas of impact include those conditions showing complex inheritance-heart disease, mental disorder, congenital abnormalities and disorders of aging, in which the increased ability to distinguish single gene effects on a multifactorial background will be exploited. Our present restricted view of the scope of mutation in disease (tables 1 and 3), determined largely by our limited ability to detect all but the grosser deletions and rearrangements, will certainly change to show enormously greater complexity and variety.
Will these advances bring about an important improvement in health care? The cynical retort is to say only at a considerable cost, because as they are currently used the techniques are undoubtedly expensive. Weatherall6" has argued on the basis of the experience with haemoglobinopathies that such measures can be very effective in financial and health terms. Although this conclusion may not apply to individually rare disorders, already relatively common conditions such as Duchenne muscular dystrophy, cystic fibrosis, and Huntington's chorea have become amenable to preventive measures using DNA analysis, so that together they constitute a group of chronically debilitating conditions that are extremely costly on any terms. In the diagnosis of tumour pathology these techniques are likely to determine treatment options at which point their benefits will become self evident. In view of the high stakes it is important that the process of "selling" these methods both to the medical profession and to the general public should be characterised by a concern for patient welfare as these advances will inevitably give rise to some awesome ethical dilemmas.
